when transcribed from enhancer regions or their neighboring loci.
Increasing evidence indicates that ncRNAs may in fact be key regulators of processes such as development, cell proliferation, apoptosis, hematopoiesis and stem cell division. Most importantly, ncRNAs have been found to be highly deregulated in tumors [12] . Such findings are of particular interest because tumor development often requires multiple genetic alterations in the genome, and many of such alterations haven been known to be in regions with no known protein-coding genes, also called 'gene desert' regions. Thus, it is reasoned that deregulation of ncRNAs may contribute to tumorigenesis. In fact, certain ncRNAs have been shown to function as oncogenes or tumor suppressors. Importantly, ncRNAs may be potential biomarkers and therapeutic candidates for cancer diagnosis and treatment. A method to detect prostate cancer antigen 3 (PCA3), a prostate cancer-associated lncRNA, in urine has been developed and approved by the Food and Drug Administration as a noninvasive prostate cancer diagnostic test [13] . The transition from ncRNA-based diagnostics to ncRNA-based therapies is also under intensive investigation.
In this Special Issue on ncRNAs in human cancer, we assemble a broad spectrum of reviewers on ncRNA biology in human cancer, ranging from basic research to translational application in oncology. We have invited some of the most influential researchers in the field of ncRNAs to help us delineate the current state-of-the-art as well as to identify opportunities and challenges for the further development of this exciting field. It is our hope that this special issue will stimulate the reader to explore diverse ways to understand the mechanisms by which ncRNAs facilitate the molecular aspects of cancer research. We would like to acknowledge and thank all authors for their valuable contributions. We also thank Dr. Alison Bentley from the Briefings Editorial Office for her guidance and support.
